Caribou Biosciences to Participate in Upcoming Investor Conferences
August 26 2024 - 4:00PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
company leadership will participate in the following event and
investor conferences:
- Morgan Stanley 22nd Annual Global
Healthcare Conference, New York, NYSeptember 4, 2024
- 2024 Wells Fargo Healthcare Conference,
Boston, MASeptember 5, 2024
During these conferences, Caribou leadership will
conduct one-on-one meetings with investors registered. For more
information, visit the Events page on Caribou’s website.
About Caribou’s novel next-generation CRISPR
platformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve activity against disease. Caribou is
advancing a pipeline of off-the-shelf cell therapies from its CAR-T
platform as readily available treatments for patients with
hematologic malignancies and autoimmune diseases. Follow us
@CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc.
contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald, PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Sep 2024 to Oct 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Oct 2023 to Oct 2024